table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 severe or critically
COVID-19 severe or critically
sarilumab sarilumab Sanofi phase 3 outside US REMAP-CAP sarilumab sarilumab Sanofi phase 3 US ARI-RAF ...
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...

0 studies excluded by filtering options 2

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons